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A B S T R A C T
Chorea-acanthocytosis (ChAc) is an uncommon basal ganglia disorder, in which the movement disorder
element may be obscured by the predominance of seizures. We report a pertinent case of a patient who
had undergone extensive evaluation for epilepsy, including intracranial EEG before ﬁnally the diagnosis
of ChAcwasmade and conﬁrmed byWestern blot.We suggest that in patientswith epilepsy, particularly
of temporal lobe origin and with onset in the third decade with inconclusive ﬁndings on clinical
examination and neuroimaging such as dyskinesias, dystonia and basal ganglia involvement, ChAc
should be considered.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Chorea-acanthocytosis (ChAc) is an autosomal-recessive disor-
der caused by mutations in the VPS13A gene coding for the chorein
protein1,2 and is recognized as a core neuroacanthocytosis
syndrome.3,4 Due to its rarity the diagnosis of ChAc is often
assigned late. Commonly, ChAc ﬁrst affects patients at about 30
years of age, usually with seizures, orofacial tics or neuropsychi-
atric symptoms followed by chorea, tongue protrusion dystonia
and head drops as typical hallmarks of the disease.5,6 Other
frequent ﬁndings are hyporeﬂexia/areﬂexia and chronically
elevated serum creatine kinase levels.
Epileptic seizures of (mesial-) temporal origin can be a
predominant feature in ChAc.7,8 Usually, seizures are controlled
with antiepileptics but individual patients may prove to be
resistant to drug treatment. We give a detailed report of a patient
with epilepsy-dominant chorea-acanthocytosis and pharmacore-
sistance (brieﬂy mentioned earlier as case 3 by Scheid et al.8) who
appears to be the only case of ChAc so far in which invasive
presurgical epilepsy evaluation has been performed.* Corresponding author. Tel.: +49 89 7095 7827; fax: +49 89 7095 6671.
E-mail address: benedikt.bader@med.uni-muenchen.de (B. Bader).
1 These authors contributed equally.
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.12.0072. Case report
Starting at the age of 31, this male electrician suffered from
somatosensory auras (hand paraesthesia), psychic auras (sensation
of fear) and abdominal auras (rising sensation, feeling sick) about
once per month. Any of these auras could evolve into a generalized
tonic–clonic seizure approximately once every three months.
Herpes encephalitis had been suspected initially on the basis of
right temporal contrast enhancement and bilateral parahippo-
campal edema on MRI that was performed after the occurrence of
the ﬁrst generalized seizures (actual images were not available for
reevaluation). This diagnosis was not conﬁrmed by cerebrospinal
ﬂuid analysis nor could suggestive postinﬂammatory changes be
seen in subsequent MRI. At the age of 35, the patient noted
progressive tics, choreatic movements, orofacial dyskinesias and
sporadic tongue and lip biting. However, the patient’s seizures did
not respond to adequate treatment with oxcarbazepine, lamo-
trigine, valproate and clonazepam.
Thus, at the age of 36 the patient underwent a presurgical
epilepsy evaluation. Despite somatosensory auras of a possible
extra-temporal origin (hand-paraesthesia), video EEG monitoring
with scalp electrodes revealed only bitemporal interictal epilepti-
form discharges and EEG seizure patterns arising from the
temporal regions on the right (eight seizure patterns observed)
and on the left (four seizure patterns). MRI demonstrated bilateral
hippocampal sclerosis, which was pronounced on the right. Givenvier Ltd. All rights reserved.
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Fig. 1. Compared to a template of healthy controls, 18F-FDG PET of this patient with seizures in the context of chorea-acanthocytosis shows bilateral hypometabolism in the
striatum (A). Interictal 18F-FDG PET shows hypometabolism in the left mesial anterior temporal lobe (B), while ictal 99mTc-ECD SPECT (C) shows focal hyperperfusion in the
same area.
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was the possibility that all seizures arose from the right mesial
temporal lobe and subsequently spread to the left. In this case,
resective epilepsy surgery with right anteromesial temporal
resection would have been a treatment option. Therefore, at the
age of 37 bilateral temporal subdural strip electrodes were
introduced surgically and video EEG monitoring was performed.
The recordings conﬁrmed bilateral temporal interictal spikes but
also documented independent bilateral temporal seizure onset
(curiously with onset more frequent from the left). This
disqualiﬁed the patient for resective surgery, in particular because
of the discrepancy between more prominent seizure onset on the
left and more prominent hippocampal sclerosis on the right. Apart
from being unlikely to control seizures, this constellation carries a
high risk of postsurgical cognitive impairment.
On one occasion during the monitoring evaluation, the patient
had nonconvulsive status epilepticus that manifested as a state of
confusion lasting for six minutes and was associated with a left
temporal seizure pattern.
An interictal cerebral 18F-FDG PET scan showed left temporal
hypometabolism, consistent with the predominant seizure onsetzone which was concordant with ictal 99mTc-ECD SPECT scan
ﬁndings showing hyperperfusion in the same area (Fig. 1B and C).
Interestingly, the striatum showedbilateral hypometabolism in 18F-
FDG PET (Fig. 1A) and hypoperfusion in 99mTc-ECD SPECT (not
shown) which were not noted at the time of the examination.
Neuropsychological evaluation at ages 35 and 39 showed constant
ﬁndings in verbal learning and verbal memory that were far below
average (1st percentile in the California verbal learning test) but
demonstrated a slight increase in working memory and recall in
neuropsychological screening instruments (mini mental state
examination was 25 and 27; SIDAM-score9 42 and 47, respectively)
most likely related to variations in the physical and mental state of
the patient at the time of the examination. Visual learning, visual
memory, executive functions and attention evaluation remained
unremarkable. Inconclusion, thediagnosisofbilateral temporal lobe
epilepsy due to suspected temporal herpes encephalitis was made.
3. Comment
By the age of 39, increasingly prominent facial tics and orofacial
dyskinesia as well as areﬂexia and personality changes in the
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diagnosis of underlying ChAc. This diagnosis was conﬁrmed by
Western blotting (absence of chorein).8 During two years of follow-
up, the patient has remained seizure free on lamotrigine and
levetiracetam.
The patient developed epilepsy nine years before the diagnosis
of ChAc was made and four years before motor symptoms of ChAc
became obvious. Earlier, his subtle orofacial dyskinesias were
misinterpreted as signs of the epilepsy syndrome since its
semiology involved oral automatisms such as lip smacking,
chewing or tongue movements. Blood tests repeatedly showed
increased creatine kinase levels, which were also attributed to
seizures, but in fact represent a typical ﬁnding in ChAc.
After the diagnosis of ChAc had been conﬁrmed, available MRI
images taken at ages 36 and 37 were reevaluated and found to be
compatible with mild caudate atrophy; prominent hippocampal
alterations were also visible. This is consistent with other reports
of neuroimaging in ChAc. In epilepsy-dominated ChAc cases
hippocampal atrophy and sclerosis can also be seen early on,8 but it
remains unclear whether these changes are related to recurrent
seizures or to the underlying neurodegenerative disorder. Howev-
er, they might be closely linked to memory dysfunction in ChAc.
Hypometabolism of the basal ganglia has repeatedly been
described in ChAc.10 The patient showed striatal impairment on
18F-FDG PET and 99mTc-ECD SPECT at an early stage of ChAc
without a prominent movement disorder. This is similar to
preclinical ﬁndings in Huntington’s disease11 and in McLeod
neuroacanthocytosis.12 In our case PET and SPECT together with
extrapyramidal clinical signs prompted the diagnosis of ChAc.
These tracer techniques were more sensitive to detect the
neurodegenerative basal ganglia process than a purely visual
analysis of the MRI when such a disorder was not suspected.
Due to the progressive neurodegenerative character of ChAc,
resective epilepsy surgery is generally inappropriate in this
condition and should only be considered in cases with seizures
of a clearly unifocal origin.8 However, this can be difﬁcult to prove
if the results from the various diagnostic methods are inconsistent.
In our patient, the degree of hippocampal sclerosis on MRI and the
ictal scalp EEG were lateralized to the right, whereas interictal
epileptic discharges were distributed between the left and the
right. On the other hand, neuropsychological assessment with a
pronounced impairment in verbal episodic memory indicated left
hemispheric dysfunction. Invasive video EEG monitoring with
intracranial electrodes is the only method to deﬁnitely identify
seizure onset zones. In our patient the invasive approach
conﬁrmed bilateral temporal seizure onset and thus ruled out
resective surgery.
In ChAc patients, bilateral or multifocal seizures appear likely.
This explains why an exact syndromic diagnosis of epilepsy is
rarely made in ChAc. In some ChAc patients without EEG video
monitoring even the differentiation between generalized or focal
epilepsy remains unsolved. This distinction, however, is of great
importance for the evaluation of the best possible treatment option
and, therefore, one should always aim for a syndromic classiﬁca-
tion of epilepsy in ChAc.
As was observed in our case, nonconvulsive status epilepticus
(NCSE) marked only by a transient confusional state may occur in
ChAc. Behavioral or cognitive changes with sudden onset and a
ﬂeeting nature may therefore indicate NCSE. An EEG can help to
identify this treatable cause of mental state deterioration.4. Conclusion
Chorea-acanthocytosis may primarily manifest with seizures.
Thus, the diagnosis of ChAc should be considered in epilepsy
patients with seizure onset between 25 and 40 years of age and
signs of an associated movement disorder such as chorea, orofacial
tics, and tongue protrusion dystonia with oral mutilation. The
clinical diagnosis of ChAc may be further supported by reduced or
absent reﬂexes as well as non-seizure related lip and tongue biting
and chronically elevated creatine kinase levels. Some of these signs
are typical features of ChAc but they can easily be misinterpreted
in the context of epilepsy. Thus, additional, neuroimaging ﬁndings,
such as striatal atrophy, hypometabolism or hypoperfusion, which
are inconsistent with isolated epilepsy, can support a clinical
diagnosis of ChAc. In the early stages of ChAc, atrophy of basal
ganglia structures is only mild and morphometric analyses of MRI
can be useful.13
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